411 results match your criteria Innovations in Clinical Neuroscience [Journal]


CNS Summit: Selected Abstracts from the 2018 Meeting.

Authors:

Innov Clin Neurosci 2018 Nov;15(11-12):S3-S19

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424577PMC
November 2018
2 Reads

Extreme Ends of Pain Sensitivity in SCN9A Mutation Variants: Case Report and Literature Review.

Innov Clin Neurosci 2018 Nov;15(11-12):33-35

Dr. Majeed is Attending Psychiatrist with the Department of Psychiatry at Natchaug Hospital in Norwich, Connecticut.

Pain insensitivity disorders are rare; however, when individuals are insensitive to pain, they are significantly more vulnerable to physical injuries, with higher morbidity and mortality rates, compared with the general population. The authors present the case of an 11-month-old male infant with SCN 9A gene mutation that resulted in congenital insensitivity to pain, while his mother, with a different mutation of the same gene, had hypersensitivity to pain. This is a rare familial presentation of the extreme ends of pain sensitivity, and might be the first such example in medical literature. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380612PMC
November 2018

Validation of an Equation Model to Predict Intracranial Pressure in Clinical Studies.

Innov Clin Neurosci 2018 Nov;15(11-12):27-29

Drs. Kasahara, Matuoka, Santos, and Cruz are with the Department of Ophthalmology, Irmandade da Santa Casa de Misericordia de Sao Paulo in Sao Paulo, Brazil.

: There has been an interest regarding the possible role intracranial pressure (ICP) plays in the pathogenesis of the glaucoma optic neuropathy. A major impediment to the understanding of the possible role of ICP on glaucoma is the reliance on alternative noninvasive methods to measure the ICP. A formula was developed to estimate the ICP for the Chinese population. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380615PMC
November 2018
1 Read

Measurement-based Care in Psychiatry-Past, Present, and Future.

Innov Clin Neurosci 2018 Nov;15(11-12):13-26

Dr. Aboraya is Chief of Psychiatry at William R. Sharpe, Jr. Hospital, Clinical Professor of Psychiatry at West Virginia School of Osteopathic Medicine, and Adjunct Faculty with the School of Public Health West Virginia University, in Weston, West Virginia.

The authors define measurement-based care (MBC) in psychiatry as the use of validated clinical measurement instruments to objectify the assessment, treatment, and clinical outcomes, including efficacy, safety, tolerability, functioning, and quality of life, in patients with psychiatric disorders. MBC includes two processes: routine assessments, such as measuring the severity of symptoms with rating scales, and the use of assessments in decision-making. MBC implementation was tested in the Texas Medication Algorithm Project and the German Algorithm Project and has been shown to improve patient outcomes. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380611PMC
November 2018
6 Reads

THE EVER-CHANGING LANDSCAPE OF THE OPIOID CRISIS: FENTANYL AND ITS ANALOGS.

Innov Clin Neurosci 2018 Nov;15(11-12):12

Board Certified Addiction Psychiatrist, Kaiser Permanente, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380613PMC
November 2018
1 Read

WHEN "CURE" BECOMES "CARE" IN ROBOTIC NEUROREHABILITATION: The Critical Role of Nurses in a Novel Sicilian Multidisciplinary Approach.

Innov Clin Neurosci 2018 Nov;15(11-12):11

Both with IRCCS Centro Neurolesi "Bonino-Pulejo" in Messina, Italy.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380614PMC
November 2018

Validation of the Russian Version of the Positive and Negative Syndrome Scale (PANSS-Ru) and Normative Data.

Innov Clin Neurosci 2018 Oct;15(9-10):32-48

Drs. Ivanova and Khan and Ms. Liharska are with VeraSci (Neurocog Trials) in Durham, North Carolina.

: The Positive and Negative Syndrome Scale (PANSS) is widely used to assess psychopathology. The Russian version (PANSSRu) has not been validated, and normative data for the Russian-speaking population currently do not exist. The aims of this study were to 1) complete linguistic validation for the PANSSRu, 2) perform psychometric validation of the Russian translation, and 3) present norms for the Russian and Belarusian population. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292716PMC
October 2018
4 Reads

Does Vitamin D Deficiency Contribute to Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus?

Innov Clin Neurosci 2018 Oct;15(9-10):25-29

Dr. Hussein is with the Internal Medicine Department.

: Neurocognitive impairment is one of the most common systemic lupus erythematosus (SLE) manifestations. However, its pathophysiology is still poorly understood. Vitamin D deficiency is a possible risk factor for cognitive impairment. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292718PMC
October 2018
18 Reads

The Assessment and Measurement of Wellness in the Clinical Medical Setting: A Systematic Review.

Innov Clin Neurosci 2018 Oct;15(9-10):14-23

Dr. Bart is with Western University of Health Sciences and Cedars-Sinai Medical Center, in Los Angeles, California.

We conducted a systematic review of the published literature relating to the assessment and measurement of wellness in order to answer the following questions: 1) What is the working definition of wellness? 2) What wellness assessment instruments have been evaluated or applied in medical settings? 3) How valid, reliable, and accessible are these wellness assessment tools? The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed for this systematic review. Studies published from1990 to 2016 on wellness assessment were identified through Medline and PsycINFO using the following keywords: "assessment" OR "evaluation" OR "measurement" AND "wellness" OR "wellbeing." Two authors independently conducted a focused analysis then reached a consensus on 23 studies that met the specific selection criteria. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292717PMC
October 2018
2 Reads

Looking Beyond the Obvious: Non-Motor Parkinsonism.

Innov Clin Neurosci 2018 Oct;15(9-10):11-13

Research Scholar, Department of Neurology, University of Louisville School of Medicine, Louisville, Kentucky.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292715PMC
October 2018
2 Reads

Gait Rehabilitation Following Neurological Disorders: Are Robotic Devices the Future?

Innov Clin Neurosci 2018 Oct;15(9-10):11-13

IRCCS Centro Neurolesi "Bonino-Pulej0", Messina, Italy nino-Pulej0", Messina, Italy.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292714PMC
October 2018
2 Reads

Ethical Reflections on Offering Patients Accelerated Resolution Therapy (ART).

Innov Clin Neurosci 2018 Jul-Aug;15(7-8):32-34. Epub 2018 Aug 1.

Dr. Howe is Professor of Psychiatry and Medicine, Uniformed Services University of the Health Sciences, in Bethesda, Maryland.

Accelerated resolution therapy (ART) is a new therapy for post-traumatic stress disorder (PTSD) that has shown exceptional promise. Compared with other standard, more evidence-based treatments, initial research has shown ART to be as effective, quicker, easier to learn, and more cost-efficient. There are ethical issues clinicians should consider before recommending ART to their patients, including the need for additional research to fully establish ART's net benefits and the difficulty patients might encounter accessing therapists trained to perform ART-based therapy. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145606PMC
August 2018
2 Reads

Worsening Choreoathetosis in Huntington's Disease with Fluoxetine, Lisdexamfetamine, and Melatonin: A Case Report.

Innov Clin Neurosci 2018 Jul-Aug;15(7-8):27-31. Epub 2018 Aug 1.

Dr. Hamilton is with the Department of Pharmacy, Veteran's Affairs Montana Medical Center-Fort Harrison, in Helena, Montana.

Cognitive, affective, and sleep disturbances can be found in patients with Huntington's disease (HD), and medications used to treat these HD-related sequela can also impact HD-related movement disorders. We present the case of a 52-year-old Caucasian man with previously undiagnosed HD who exhibited significant choreoathetoid movements that improved with discontinuation of fluoxetine and lisdexamfetamine upon hospital admission. Following diagnosis of HD through genetic testing, he was administered 5mg of oral melatonin on two consecutive evenings, which resulted in worsening choreoathetosis. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145609PMC
August 2018
12 Reads

Transition from Obsession to Delusion in Schizo-obsessive Disorder: A Case Report and Literature Overview.

Innov Clin Neurosci 2018 Jul-Aug;15(7-8):23-26. Epub 2018 Aug 1.

Drs. Scotti-Muzzi and Saide are with the Psychiatry Unit, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Brazil.

Schizo-obsessive disorder has been proposed to classify those who show schizophrenia and obsessive compulsive disorder (OCD) diagnoses. This subgroup has recently shown to be much more prevalent than previously thought, as well as presenting distinct clinical, phenomenological and neurobiological features from the parental diseases. We present a case report of a 32-year-old man who first manifested obsessive-compulsive symptoms (OCS) in his early twenties, followed by emergence of consistent negative schizophrenia symptoms, as well as intermittent aggressive behavior. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145607PMC
August 2018
8 Reads

Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge.

Innov Clin Neurosci 2018 Jul-Aug;15(7-8):20-22. Epub 2018 Aug 1.

Drs. Teo, Wong and Tan are with the Department of Psychological Medicine, Changi General Hospital, Singapore.

Neuroleptic malignant syndrome (NMS) is a rare, idiosyncratic, but life-threatening adverse reaction associated with the use of antipsychotic drugs. It is characterized by a tetrad of fever, rigidity, autonomic instability, and altered mental status. Failure to diagnose NMS early and institute appropriate treatment can result in serious medical complications and death. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145603PMC
August 2018
22 Reads

Can Youtube Disseminate Dementia Knowledge to Singapore Chinese?

Authors:
Benjamin K P Woo

Innov Clin Neurosci 2018 Jul-Aug;15(7-8):14. Epub 2018 Aug 1.

Department of Psychiatry & Biobehavioral Science, University of California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145601PMC
August 2018
2 Reads

Author Response.

Innov Clin Neurosci 2018 Jul-Aug;15(7-8):13. Epub 2018 Aug 1.

Research Associate, University of Louisville School of Medicine, Louisville, Kentucky.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145602PMC
August 2018
2 Reads

Regarding Zika Microcephaly.

Innov Clin Neurosci 2018 Jul-Aug;15(7-8):12. Epub 2018 Aug 1.

Sanitation, Medical Academic Center, Bangkok, Thailand.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145604PMC
August 2018
1 Read

Metabolic Changes in Patients with Schizophrenia Switched From Olanzapine to Asenapine or Clozapine.

Innov Clin Neurosci 2018 Jul-Aug;15(7-8):11-12. Epub 2018 Aug 1.

Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital, Hiroshima, Japan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145608PMC
August 2018
1 Read

PNEUMOCEPHALUS: IS THE NEEDLE SIZE SIGNIFICANT?

Innov Clin Neurosci 2018 Feb;15(1-2):14

Dr. Kolikonda is from the Department of Neurology, Dr. Jayakumar is from the Division of Infectious Diseases, Dr. Sriramula is with Internal Medicine, and Dr. Lippmann is from the Department of Psychiatry, University of Louisville School of Medicine, Louisville, Kentucky.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042981PMC
February 2018
2 Reads

ACUTE SCHIZOPHRENIA-LIKE PSYCHOTIC DISORDER: A CRITICAL APPRAISAL OF ITS DIAGNOSTIC VALIDITY THROUGH A CASE SERIES.

Innov Clin Neurosci 2018 Feb;15(1-2):12-13

Drs. López-Díaz and Lara are with the UGC Salud Mental, Hospital Universitario Virgen Macarena in Seville, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042983PMC
February 2018
2 Reads

MARIJUANA ON THE BRAIN- A CONCERN.

Innov Clin Neurosci 2018 Feb;15(1-2):12

Dr. Naik is a Research Scholar in the Department of Neurology.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042982PMC
February 2018
3 Reads

Atrial Fibrillation and Injected Aripiprazole: A Case Report.

Innov Clin Neurosci 2018 Jun;15(5-6):43-45

Drs. Stefatos and Ha are with the Department of Psychiatry at Queens University in Kingston, Ontario, Canada.

Aripiprazole is a widely clinically employed antipsychotic drug for a range of indications. It has unusual pharmacodynamics as a dopamine D receptor partial-agonist with complex interactions with serotonin receptors and, a relatively unusual long elimination half-life. Although other atypical antipsychotics have been associated with an increased risk of atrial fibrillation, aripiprazole is considered to be relatively neutral in regard to its cardiac risk. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040719PMC
June 2018
20 Reads

Development of a Behavioral Health Stigma Measure and Application of Machine Learning for Classification.

Innov Clin Neurosci 2018 Jun;15(5-6):34-42

Drs. Tokmic and Hadzikadic are with the Department of Software & Information Systems at the University of North Carolina, in Charlotte, North Carolina.

Given the growing public health importance of measuring the change in mental health stigma over time, the goal of this study was to demonstrate the potential for using machine learning as a tool to analyze patterns of social stigma as a complement to traditional research methods. A total of 1,904 participants were recruited through Sona Systems, Ltd (Tallinn, Estonia), an experiment management system for online research, to complete a self-reported survey. The collected data were used to develop a new measure of mental (behavioral) health stigma. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040723PMC
June 2018
3 Reads

Delirium and Psychotic Symptoms Associated with Hyperglycemia in a Patient with Poorly controlled Type 2 Diabetes Mellitus.

Innov Clin Neurosci 2018 Jun;15(5-6):30-33

Dr. Lopes is with the Faculty of Medicine at the University of Porto in Porto, Portugal.

Delirium, acute confusional states, and secondary psychosis have been associated with several medical conditions, including endocrine disorders. In the context of diabetes mellitus (DM), it has been mostly related to hypoglycemia and rarely occurs in association with hyperglycemia, outside of the context of a hyperglycemic hyperosmolar state or diabetic ketoacidosis. Here, we describe a case of delirium and psychotic symptoms associated with hyperglycemia in a patient with poorly controlled Type 2 DM as an attempt to alert clinicians to this rare association. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040722PMC
June 2018
25 Reads

Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials.

Innov Clin Neurosci 2018 Jun;15(5-6):22-29

Dr. Sheehan is with the University of South Florida College of Medicine in Tampa, Florida.

In two Phase III, randomized, placebo-controlled trials (NCT01718483 and NCT01718509 at ClinicalTrials.gov), lisdexamfetamine dimesylate (LDX) reduced binge eating days/week in adults with moderate-to-severe binge eating disorder (BED). We describe the effects of LDX (50mg and 70mg) on the Sheehan Disability Scale (SDS; exploratory endpoint) from both studies. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040726PMC
June 2018
6 Reads

Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study.

Innov Clin Neurosci 2018 Jun;15(5-6):17-21

Drs. Guerdjikova and McElroy and Ms. Mori are with the Lindner Center of HOPE in Mason, Ohio, and the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine in Cincinnati, Ohio.

The goal of this study was to obtain preliminary data on the usefulness of the combination of phentermine and topiramate extended release (phentermine-topiramate) in binge-eating disorder (BED) associated with obesity or overweight. Ten participants with BED and obesity or overweightness with at least one weight-related complication received phentermine-topiramate in an open-label, prospective, 12-week trial. The primary outcome measure was change in weight. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040720PMC
June 2018
2 Reads

Valbenazine and Deutetrabenazine for Tardive Dyskinesia.

Innov Clin Neurosci 2018 Jun;15(5-6):13-16

Dr. Touma is with the William Jennings Bryan Dorn VA Medical Center Community-based Outpatient Clinic in Anderson, South Carolina.

Tardive dyskinesia (TD) is a medication-induced permanent movement disorder with no United States Food and Drug Administration (FDA)-approved treatments prior to 2017. Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or discontinuation due to a risk of psychiatric decompensation. Valbenazine and deutetrabenazine were recently approved by the FDA for the treatment of TD. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040721PMC
June 2018
13 Reads

EFFECTIVE PAIN CONTROL IN HUTCHINSON-GILFORD PROGERIA SYNDROME.

Innov Clin Neurosci 2018 Jun;15(5-6):11-12

Dr. Majeed is an attending psychiatrist with Department of Psychiatry, Natchaug Hospital in Norwich, Connecticut.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040725PMC
June 2018
12 Reads

KRATOM AND THE OPIOID CRISIS.

Authors:
Durga Bestha

Innov Clin Neurosci 2018 Jun;15(5-6):11

Dr. Bestha is with the Carolinas Healthcare System in Charlotte, North Carolina.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040724PMC
June 2018
12 Reads

Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder.

Innov Clin Neurosci 2018 Apr;15(3-4):37-42

Drs. Targum and Murphy are with Bracket Global LLC in Boston, Massachusetts.

: The assessment of patients with generalized anxiety disorder (GAD) to deteremine whether a medication intervention is necessary is not always clear and might benefit from a second opinion. However, second opinions are time consuming, expensive, and not practical in most settings. We obtained independent, second opinion reviews of the primary clinician's assessment via audio-digital recording. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919431PMC
April 2018
9 Reads

Is Electroconvulsive Therapy a Treatment for Depression Following Traumatic Brain Injury?

Innov Clin Neurosci 2018 Apr;15(3-4):43-46

Dr. Srienc is with the Medical Scientist Training Program & Graduate Program in Neuroscience at the University of Minnesota in Minneapolis-St. Paul, Minnesota.

Traumatic brain injury (TBI) can be caused by blunt or penetrating injury to the head. The pathophysiological evolution of TBI involves complex biochemical and genetic changes. Common sequelae of TBI include seizures and psychiatric disorders, particularly depression. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906090PMC
April 2018
3 Reads

Psychosis in a Child with Atypical Autism: A Case Report and a Brief Review of the Association of Psychosis and Autism.

Innov Clin Neurosci 2018 Apr;15(3-4):33-36

Drs. Sahoo, Singla, and Singh are Senior Residents.

Recent studies have shown that individuals with an autism spectrum disorder (ASD) are at an increased risk of developing psychosis. Diagnosing psychosis in such individuals can be challenging when they present with symptoms at a young age. A careful history and thorough assessment are essential for proper diagnosis to avoid mislabeling certain behavioral problems encountered among children with ASD. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906088PMC
April 2018
1 Read

Comorbid Insomnia and Psychiatric Disorders: An Update.

Innov Clin Neurosci 2018 Apr;15(3-4):28-32

Dr. Khurshid is Clinical Associate Profressor and Chief of the Neuromodulation and Sleep Disorders Program in the Department of Psychiatry at the University of Florida College of Medicine in Gainsville, Florida.

Insomnia is a clinical problem of significant public health importance. Insomnia can be a symptom or harbinger of other psychiatric disorders. Insomnia can also be comorbid with other psychiatric disorders, thereby adding to the medical burden and increasing the risk of psychiatric relapse. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906087PMC
April 2018
3 Reads

Effects of Statins and Cholesterol on Patient Aggression: Is There a Connection?

Innov Clin Neurosci 2018 Apr;15(3-4):24-27

Drs. Leppien, Mulcahy, Demler, and Trigoboff are with Buffalo Psychiatric Center, New York State Office of Mental Health, and State University of New York, University at Buffalo School of Pharmacy and Pharmaceutical Sciences in Buffalo, New York.

: Psychiatric adverse effects, including aggression, have been reported with the use of statin medications; however, there is little data to support or refute the theory that statins or low serum cholesterol do in fact increase a patient's risk of aggression. : This study examined 1) statin use and increased aggression, measured by the requirement of either emergent psychiatric intervention referred to as "Code Green" (CG) or "Restraint and Seclusion" (RS) and 2) cholesterol level and increased aggression in psychiatric inpatients. : Patient charts from January 1, 2011, to December 31, 2015 were reviewed. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906086PMC
April 2018
12 Reads

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury.

Innov Clin Neurosci 2018 Apr;15(3-4):17-23

Drs. Borghol, Onor, and Jamero are with the College of Pharmacy at Xavier University of Louisiana in New Orleans, Louisiana.

: The authors sought to assess the literature evidence on the efficacy of modafinil use in patients with fatigue or excessive daytime sleepiness (EDS) secondary to traumatic brain injury (TBI). : A literature search of Medline and PubMed was performed using the EBSCOhost database. Primary literature, observational studies, meta-analyses, case reports, and systematic reviews were assessed for content regarding modafinil and psychostimulant use in patients with TBI. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906085PMC
April 2018
6 Reads

Neuroscience is the Next Oncology.

Authors:
Michael D Ehlers

Innov Clin Neurosci 2018 Apr;15(3-4):15-16

Dr. Ehlers is with Biogen in Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906084PMC
April 2018
1 Read

PROLACTIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA WHO WERE SWITCHED FROM DAILY TO ONCE-MONTHLY ARIPIPRAZOLE TREATMENT.

Innov Clin Neurosci 2018 Apr;15(3-4):12-13

Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital, Hiroshima, Japan. Dr. Nagamine is with the Department of Psychiatric Internal Medicine, Sunlight Brain Research Center, Yamaguchi, Japan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906083PMC
April 2018
1 Read

OLANZAPINE AND DIABETIC KETOACIDOSIS: WHAT IS THE UNDERLYING MECHANISM?

Innov Clin Neurosci 2018 Apr;15(3-4):11

Dr. Nagamine is with the Department of Psychiatric Internal Medicine, Sunlight Brain Research Center, Yamaguchi, Japan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906082PMC
April 2018
2 Reads

DISCUSSING ANT1 ROLE IN AMYOTROPHIC LATERAL SCLEROSIS PATHOGENESIS.

Innov Clin Neurosci 2018 04;15(3-4):11

All with the IRCCS Centro Neurolesi "Bonino Pulejo" in Messina, Italy.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906081PMC
April 2018
3 Reads

Narcolepsy in Adolescence-A Missed Diagnosis: A Case Report.

Innov Clin Neurosci 2017 Jul-Aug;14(7-8):20-23. Epub 2017 Aug 1.

Dr. Gupta is a junior resident, Dr. Sahoo is a senior resident, and Dr. Grover is a professor in the Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Narcolepsy is an uncommon sleep cycle disorder with a usual onset in adolescence, but it is often misdiagnosed and underdiagnosed. Rarely is the tetrad of excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis seen in patients. The clinical characteristics of narcolepsy are often confused with many psychiatric and neurologic disorders. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880369PMC
August 2017
4 Reads

Methadone Treatment of Opiate Addiction: A Systematic Review of Comparative Studies.

Innov Clin Neurosci 2017 Jul-Aug;14(7-8):8-19. Epub 2017 Aug 1.

Drs. Ali and Tahir are with the Smart Choice Treatment Center in Franklin, Tennessee. Ms. Malik is a Research Associate with the Smart Choice Treatment Center in Franklin, Tennessee. Dr. Jabeen is Site Director of the VA Residency Training Program in Nashville and Murfreesboro, Tennessee, and Site Director of the Geriatric Fellowship Program and Adjunct Associate Professor at Vanderbilt University, Nashville, Tennessee.

Opiate misuse is a chronic relapsing disease that has become an epidemic in the United States. Methadone is the mainstay of treatment for opiate addiction and has been researched widely. Recently, new avenues of treatment have been researched and developed. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880371PMC
August 2017
4 Reads

Immersive Virtual Reality Therapy with Myoelectric Control for Treatment-resistant Phantom Limb Pain: Case Report.

Innov Clin Neurosci 2017 Jul-Aug;14(7-8):3-7. Epub 2017 Aug 1.

Dr. Chau, Dr. Ta, Dr. Humbert, Dr. Hata, and Dr. Tran are with the Department of Physical Medicine & Rehabilitation at Loma Linda University Health. Mr. Phelan is with the Research Institute C3RI at Sheffield Hallam University.

Phantom limb pain is a condition frequently experienced after amputation. One treatment for phantom limb pain is traditional mirror therapy, yet some patients do not respond to this intervention, and immersive virtual reality mirror therapy offers some potential advantages. We report the case of a patient with severe phantom limb pain following an upper limb amputation and successful treatment with therapy in a custom virtual reality environment. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880370PMC
August 2017
5 Reads

Trazodone for Insomnia: A Systematic Review.

Innov Clin Neurosci 2017 Jul-Aug;14(7-8):24-34. Epub 2017 Aug 1.

Mr. Jaffer is with the Faculty of Medicine, Cairo University, Egypt. Ms. Chang is with the University of California Los Angeles, Los Angeles, California. Dr. Vanle, Dr. Dang, Ms. Loera, Dr. Abdelmesseh, and Dr. Danovitch are with the Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center, Los Angeles, California. Dr. Steiner is with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. Dr. IsHak is with the Department of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center, Los Angeles, California, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

While trazodone is approved for the treatment of depression, the off-label use of this medication for insomnia has surpassed its usage as an antidepressant. In this systematic review, we examined the evidence for the efficacy and safety of trazodone for insomnia. A literature search was conducted using MEDLINE/PubMed databases from the past 33 years (1983-2016) and the keywords insomnia, trazodone, sedative, treatment, and hypnotics. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842888PMC
August 2017
24 Reads

Wants Talk Psychotherapy but Cannot Talk: EMDR for Post-stroke Depression with Expressive Aphasia.

Innov Clin Neurosci 2018 Feb;15(1-2):45-48

Dr. Jeffrey Guina is with the Department of Psychiatry, Wright State University Boonshoft School of Medicine in Dayton, Ohio, and the 88th Medical Group, Wright-Patterson Medical Center, Wright-Patterson Air Force Base in Ohio.

While post-stroke depression (PSD) is a common sequelae of stroke, many stroke survivors also have expressive aphasia (i.e., the inability to produce spoken or written language), which limits or prevents treating depression with talk psychotherapy. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819721PMC
February 2018
6 Reads

Cognitive Impairment Associated with Cancer: A Brief Review.

Innov Clin Neurosci 2018 Feb;15(1-2):36-44

Drs. Pendergrass and Targum are with Bracket Global and Clintara LLC, A Bracket Company, in Boston, Massachusetts.

This brief review explores the areas of cognitive impairment that have been observed in cancer patients and survivors, the cognitive assessment tools used, and the management of the observed cognitive changes. Cognitive changes and impairment observed in patients with cancer and those in remission can be related to the direct effects of cancer itself, nonspecific factors or comorbid conditions that are independent of the actual disease, and/or the treatments or combination of treatments administered. Attention, memory, and executive functioning are the most frequently identified cognitive domains impacted by cancer. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819720PMC
February 2018
6 Reads

The Benefit of Mirtazapine in the Treatment of Progressive Multifocal Leukoencephalopathy in a Young HIV-positive Patient: A Case Report.

Innov Clin Neurosci 2018 Feb;15(1-2):33-35

Drs. Mullins, Sandoval, and Ramos-Duran are with the Department of Radiology.

Highly active antiretroviral therapy is well-established in the treatment of human immunodeficiency virus (HIV)-positive patients. Nonadherence with therapy regimens often leads to the occurrence of opportunistic infections that further complicate treatment and challenge the treating physician. We report a young HIV-positive patient who suffered from progressive multifocal leukoencephalopathy caused by the human John Cunningham virus and showed objective clinical improvement after adding mirtazapine to the treatment regimen, an observation that is supported by the emerging literature. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819719PMC
February 2018
7 Reads

Lower-extremity Dynamometry as a Novel Outcome Measure in a Double-blind, Placebo-controlled, Feasibility Trial of Intravenous Immunoglobulin (IVIG) for HIV-associated Myelopathy.

Innov Clin Neurosci 2018 Feb;15(1-2):28-32

Drs. Robinson-Papp, George, Nmashie and Simpson are with the Department of Neurology.

: Open-label data suggest that intravenous immunoglobulin (IVIG) might improve lower-extremity strength in human immunodeficiency virus (HIV)-associated myelopathy (HIVM), a rare but debilitating neurologic complication of HIV. We sought to determine the feasibility of testing the efficacy of IVIG for HIVM more rigorously. : We conducted a randomized, double-blind, placebo-controlled feasibility trial of IVIG for HIVM, using dynamometry as an outcome measure (Clinical Trial No. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819718PMC
February 2018
5 Reads